Xiaoling Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xiaoling Li has a total of 504 co-authors. Here are the top co-authors by number of shared publications:
Qing Xu
National Institute of Environmental Health Sciences
14 shared publications- Shuang Tang
Cancer Institute Fudan University Shanghai Cancer Center Shanghai China
12 shared publications - Jian-Liang Li
National Institute of Environmental Health Sciences
9 shared publications Ming Ji
Molecular and Cellular Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, USA
9 shared publications- Igor Shats
National Institute of Environmental Health Sciences
8 shared publications Wei Fan
8 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Research Square
Prolonged methionine restriction induces liver cancer persistence through RNA G-quadruplex-mediated translational inhibition of HNF4α
Methionine restriction, a dietary intervention that limits the intake of the essential amino acid methionine and imposes nutritional stress on cancer cells, has emerged as a potentially less toxic anti-cancer strategy. By cell-autonomously disrupting one-carbon metabolism, epigenetic regulation, and redox homeostasis, methionine restriction can inhibit tumor growth and enhance the sensitivity of certain human cancers to chemotherapy and radiotherapy in. However, because methionine is essential for normal cellular function, prolonged restriction may lead to adverse outcomes, including immune dysfunction, bone loss, and enhanced stress resistance. Consequently, the long-term influence of methionine restriction on cancer progression is complex and remains poorly understood. Here we report that prolonged methionine restriction in epithelial human liver cancer cells reduces translation of hepatocyte nuclear factor 4α (HNF4α), a master regulator of hepatocyte identity. The action leads to the formation of drug-tolerant persister cells that phenotypically resemble HNF4α-negative mesenchymal liver cancer cells. Mechanistically, we show that the 5’-untranslated region (5’-UTR) of the HNF4A mRNA harbors highly conserved RNA G-quadruplex (rG4) sequences recognized and bound by an RNA binding protein SRSF1, which facilitates HNF4α translation. Prolonged methionine restriction activates AMPK, reducing the binding of SRSF1 to HNF4A rG4 and attenuating HNF4α translation. Notably, overexpression of HNF4α from an rG4-free construct or inhibition of AMPK restores the sensitivity of established persisters to methionine restriction. Collectively, our findings uncover a post-transcriptional mechanism linking metabolic stress to remodeling of tumor cell identity and identify the AMPK-SRSF1-HNF4α axis as a potential therapeutic target for drug-resistant and metastatic liver cancer.
- 21 September 2026
- Published by Springer Nature in Research Square
Open AccessProlonged methionine restriction induces liver cancer persistence through RNA G-quadruplex-mediated translational inhibition of HNF4α
Methionine restriction, a dietary intervention that limits the intake of the essential amino acid methionine and imposes nutritional stress on cancer cells, has emerged as a potentially less toxic anti-cancer strategy. By cell-autonomously disrupting one-carbon metabolism, epigenetic regulation, and redox homeostasis, methionine restriction can inhibit tumor growth and enhance the sensitivity of certain human cancers to chemotherapy and radiotherapy in. However, because methionine is essential for normal cellular function, prolonged restriction may lead to adverse outcomes, including immune dysfunction, bone loss, and enhanced stress resistance. Consequently, the long-term influence of methionine restriction on cancer progression is complex and remains poorly understood. Here we report that prolonged methionine restriction in epithelial human liver cancer cells reduces translation of hepatocyte nuclear factor 4α (HNF4α), a master regulator of hepatocyte identity. The action leads to the formation of drug-tolerant persister cells that phenotypically resemble HNF4α-negative mesenchymal liver cancer cells. Mechanistically, we show that the 5’-untranslated region (5’-UTR) of the HNF4A mRNA harbors highly conserved RNA G-quadruplex (rG4) sequences recognized and bound by an RNA binding protein SRSF1, which facilitates HNF4α translation. Prolonged methionine restriction activates AMPK, reducing the binding of SRSF1 to HNF4A rG4 and attenuating HNF4α translation. Notably, overexpression of HNF4α from an rG4-free construct or inhibition of AMPK restores the sensitivity of established persisters to methionine restriction. Collectively, our findings uncover a post-transcriptional mechanism linking metabolic stress to remodeling of tumor cell identity and identify the AMPK-SRSF1-HNF4α axis as a potential therapeutic target for drug-resistant and metastatic liver cancer.
- Open Access
Host soluble inositol phosphate signaling promotes coronavirus replication
Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.
Open AccessHost soluble inositol phosphate signaling promotes coronavirus replication
Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.
- Open Access
- 13 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (7) , 1830-1857
Paneth cell SIRT1 deficiency increases intestinal stress resistance by modulating the gut microbiota
Paneth cells, intestine-originated innate immune-like cells, are important for maintenance of the intestinal stem cell niche, gut microbiota, and gastrointestinal barrier. Dysfunctional Paneth cells under pathological conditions are a site of origin for intestinal inflammation. However, mechanisms underlying stress-induced Paneth cell dysregulation remain unclear. Here, we report that SIRT1, the most conserved mammalian NAD + -dependent protein deacetylase and a well-known genetic repressor of inflammation, cell-autonomously suppresses Paneth cell function and sensitizes the gut epithelium to environmental stress. Specifically, deletion of Paneth cell SIRT1 in mice elevates Wnt signaling and ATF4/endoplasmic reticulum stress pathway in Paneth cells. These molecular alterations are coupled with increased Paneth cell abundance and enhanced anti-microbial peptide production in young mice, improved protection against intestinal immune cell expansion in aged mice, and increased resistance to chemically induced colitis. Using microbiota-depleted mice with or without fecal transplantation, we further demonstrate that Paneth cell SIRT1 deficiency ameliorates colitis by interacting with the gut microbiota. Collectively, our findings uncover an unanticipated function of Paneth cell SIRT1 in conferring stress sensitivity in the gut epithelium.
- 13 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (7) , 1830-1857
Open AccessPaneth cell SIRT1 deficiency increases intestinal stress resistance by modulating the gut microbiota
Paneth cells, intestine-originated innate immune-like cells, are important for maintenance of the intestinal stem cell niche, gut microbiota, and gastrointestinal barrier. Dysfunctional Paneth cells under pathological conditions are a site of origin for intestinal inflammation. However, mechanisms underlying stress-induced Paneth cell dysregulation remain unclear. Here, we report that SIRT1, the most conserved mammalian NAD + -dependent protein deacetylase and a well-known genetic repressor of inflammation, cell-autonomously suppresses Paneth cell function and sensitizes the gut epithelium to environmental stress. Specifically, deletion of Paneth cell SIRT1 in mice elevates Wnt signaling and ATF4/endoplasmic reticulum stress pathway in Paneth cells. These molecular alterations are coupled with increased Paneth cell abundance and enhanced anti-microbial peptide production in young mice, improved protection against intestinal immune cell expansion in aged mice, and increased resistance to chemically induced colitis. Using microbiota-depleted mice with or without fecal transplantation, we further demonstrate that Paneth cell SIRT1 deficiency ameliorates colitis by interacting with the gut microbiota. Collectively, our findings uncover an unanticipated function of Paneth cell SIRT1 in conferring stress sensitivity in the gut epithelium.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-6 from PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Figure S1. Bio-ID screening reveals PI3Kβ, but not PI3Kα, as a selective interactor of EPHA2 in PTEN-null cancer cells. Figure S2. PTEN acts as a protein tyrosine phosphatase regulating PI3Kβ- EPHA2 interaction through dephosphorylation of tyrosine-962 (Y962) on PI3Kβ and impact tumorigenesis. Figure S3. Generation of a new antibody to detect phospho-PI3KβY962 levels. Figure S4. PI3Kβ and EPHA2 upregulate pERK/c-MYC and pAKT signaling in PTEN null cancer. Figure S5. Compound library screening identifies dasatinib as an inhibitor of PI3KβY962 phosphorylation that effectively inhibits PTEN-null tumor growth. Figure S6. Phosphorylation of PI3Kβ is a druggable target to treat PTEN-null tumors in vivo.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-6 from PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Figure S1. Bio-ID screening reveals PI3Kβ, but not PI3Kα, as a selective interactor of EPHA2 in PTEN-null cancer cells. Figure S2. PTEN acts as a protein tyrosine phosphatase regulating PI3Kβ- EPHA2 interaction through dephosphorylation of tyrosine-962 (Y962) on PI3Kβ and impact tumorigenesis. Figure S3. Generation of a new antibody to detect phospho-PI3KβY962 levels. Figure S4. PI3Kβ and EPHA2 upregulate pERK/c-MYC and pAKT signaling in PTEN null cancer. Figure S5. Compound library screening identifies dasatinib as an inhibitor of PI3KβY962 phosphorylation that effectively inhibits PTEN-null tumor growth. Figure S6. Phosphorylation of PI3Kβ is a druggable target to treat PTEN-null tumors in vivo.
- Top Cited PapersOpen Access
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
NAPRT-mediated deamidated NAD biosynthesis enhances colon tissue resiliency and suppresses tumorigenesis
Nicotinamide adenine dinucleotide (NAD) is synthesized through both amidated salvage and deamidated pathways. Although NAD-producing enzymes are often overexpressed in cancer cells to meet the high metabolic demands of rapid proliferation and are considered oncogenic, we report that physiological levels of nicotinic acid phosphoribosyl transferase (NAPRT), the first enzyme in the Preiss-Handler arm of the deamidated pathways, suppress tumorigenesis. We show that NAPRT is enriched in gut epithelial cells, where it sustains the NAD pool for an efficient response to stress-induced acute NAD depletion. Consequently, NAPRT deficiency impairs the activity of poly-(ADP-ribose) polymerases and DNA repair, sensitizes mice to chemical-induced colitis and tumorigenesis, as well as to age-associated spontaneous tumor development. Moreover, low NAPRT expression correlates with poor prognosis in several human cancer types. Thus, homeostatic levels of deamidated NAD biosynthesis contribute to tumor suppression, and boosting this pathway may offer a strategy for cancer prevention.
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessNAPRT-mediated deamidated NAD biosynthesis enhances colon tissue resiliency and suppresses tumorigenesis
Nicotinamide adenine dinucleotide (NAD) is synthesized through both amidated salvage and deamidated pathways. Although NAD-producing enzymes are often overexpressed in cancer cells to meet the high metabolic demands of rapid proliferation and are considered oncogenic, we report that physiological levels of nicotinic acid phosphoribosyl transferase (NAPRT), the first enzyme in the Preiss-Handler arm of the deamidated pathways, suppress tumorigenesis. We show that NAPRT is enriched in gut epithelial cells, where it sustains the NAD pool for an efficient response to stress-induced acute NAD depletion. Consequently, NAPRT deficiency impairs the activity of poly-(ADP-ribose) polymerases and DNA repair, sensitizes mice to chemical-induced colitis and tumorigenesis, as well as to age-associated spontaneous tumor development. Moreover, low NAPRT expression correlates with poor prognosis in several human cancer types. Thus, homeostatic levels of deamidated NAD biosynthesis contribute to tumor suppression, and boosting this pathway may offer a strategy for cancer prevention.
- Open Access
- 17 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (3) , 521-540
PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Loss of the tumor-suppressor PTEN drives cancer progression and therapeutic resistance, yet no targeted therapies exist for PTEN-deficient tumors. In this study, we identify a critical druggable mechanism in which PTEN loss induces PI3Kβ phosphorylation for tumorigenesis. Using the BioID interactome, we uncovered a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells, driven by p-PI3KβY962. PTEN functions as a tyrosine phosphatase that normally dephosphorylates p-PI3KβY962. In PTEN-deficient contexts, enhanced p-PI3KβY962 forms a complex with EPHA2 and SRC, in which both kinases contribute to PI3Kβ phosphorylation, activating oncogenic pERK/c-MYC and pAKT pathways. We developed a selective p-PI3KβY962 antibody detecting p-PI3KβY962 in PTEN-deficient tumors across preclinical models and clinical tumor specimens. Disrupting p-PI3KβY962 suppressed tumor growth in multiple PTEN-null models. Dasatinib, an FDA-approved SRC/EPHA2 inhibitor, effectively reduced p-PI3KβY962 and inhibited tumor progression in PTEN-null but not PTEN wild-type tumors. These findings establish p-PI3KβY962 as a druggable target and biomarker for developing targeted therapy in PTEN-deficient cancers beyond conventional PI3K kinase inhibition. Significance: We revealed a critical new mechanism that PTEN loss induces PI3Kβ phosphorylation and EPHA2/SRC/p-PI3KβY962 complex signaling to drive tumorigenesis. This work directs pharmaceutical development of p-PI3KβY962 inhibitors and biomarker-driven clinical trials repurposing dasatinib for PTEN-deficient solid tumor treatment, with potential to significantly improve outcomes of broad patients with PTEN-deficient tumors.
- 17 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (3) , 521-540
Open AccessPTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Loss of the tumor-suppressor PTEN drives cancer progression and therapeutic resistance, yet no targeted therapies exist for PTEN-deficient tumors. In this study, we identify a critical druggable mechanism in which PTEN loss induces PI3Kβ phosphorylation for tumorigenesis. Using the BioID interactome, we uncovered a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells, driven by p-PI3KβY962. PTEN functions as a tyrosine phosphatase that normally dephosphorylates p-PI3KβY962. In PTEN-deficient contexts, enhanced p-PI3KβY962 forms a complex with EPHA2 and SRC, in which both kinases contribute to PI3Kβ phosphorylation, activating oncogenic pERK/c-MYC and pAKT pathways. We developed a selective p-PI3KβY962 antibody detecting p-PI3KβY962 in PTEN-deficient tumors across preclinical models and clinical tumor specimens. Disrupting p-PI3KβY962 suppressed tumor growth in multiple PTEN-null models. Dasatinib, an FDA-approved SRC/EPHA2 inhibitor, effectively reduced p-PI3KβY962 and inhibited tumor progression in PTEN-null but not PTEN wild-type tumors. These findings establish p-PI3KβY962 as a druggable target and biomarker for developing targeted therapy in PTEN-deficient cancers beyond conventional PI3K kinase inhibition. Significance: We revealed a critical new mechanism that PTEN loss induces PI3Kβ phosphorylation and EPHA2/SRC/p-PI3KβY962 complex signaling to drive tumorigenesis. This work directs pharmaceutical development of p-PI3KβY962 inhibitors and biomarker-driven clinical trials repurposing dasatinib for PTEN-deficient solid tumor treatment, with potential to significantly improve outcomes of broad patients with PTEN-deficient tumors.
- 25 July 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (2) , 105-107
Host–microbe interactions in NAD+ metabolism
- 25 July 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (2) , 105-107
Host–microbe interactions in NAD+ metabolism
- Open Access
- 13 September 2024
- Published by Wiley in Journal of Pineal Research
- Vol. 76 (6) , e13007
Melatonin Prevents Thioacetamide–Induced Gut Leakiness and Liver Fibrosis Through the Gut–Liver Axis via Modulating Sirt1‐Related Deacetylation of Gut Junctional Complex and Hepatic Proteins
Intestinal barrier dysfunction with high serum endotoxin is common in patients with liver fibrosis, but the mechanisms underlying liver fibrosis remain unclear. Melatonin is a well‐recognized antioxidant and an anti‐inflammatory agent that benefits multiple organs. However, the beneficial effects of melatonin on gut leakiness–associated liver fibrosis have not been systemically studied. Here, we investigated the protective mechanisms of melatonin against thioacetamide (TAA)–induced gut barrier dysfunction and hepatic fibrosis by focusing on posttranslational protein modifications through the gut–liver axis. Our results showed that gut leakiness markers, including decreased gut tight/adherens junction proteins (TJ/AJs) with increased intestinal deformation, apoptosis, and serum endotoxin, were observed early at 1 week after TAA exposure. Liver injury, apoptosis, and fibrosis were prominent at 2 and 4 weeks. Mechanistically, we found that gut TJ/AJs were hyper‐acetylated, followed by ubiquitin‐dependent proteolysis, leading to their degradation and gut leakiness. Gut dysbiosis, hepatic protein hyper‐acetylation, and SIRT1 downregulation were also observed. Consistently, intestinal Sirt1 deficiency greatly enhanced protein hyper‐acetylation, gut leakiness, endotoxemia, and liver fibrosis. Pretreatment with melatonin prevented or improved all these changes in both the gut and liver. Furthermore, melatonin blunted protein acetylation and injury in TAA–exposed T84 human intestinal and AML12 mouse liver cells. Overall, this study demonstrated novel mechanisms by which melatonin prevents gut leakiness and liver fibrosis through the gut–liver axis by attenuating the acetylation of intestinal and hepatic proteins. Thus, melatonin consumption can become a potentially safe supplement for liver fibrosis patients by preventing protein hyper‐acetylation and gut leakiness.
- 13 September 2024
- Published by Wiley in Journal of Pineal Research
- Vol. 76 (6) , e13007
Open AccessMelatonin Prevents Thioacetamide–Induced Gut Leakiness and Liver Fibrosis Through the Gut–Liver Axis via Modulating Sirt1‐Related Deacetylation of Gut Junctional Complex and Hepatic Proteins
Intestinal barrier dysfunction with high serum endotoxin is common in patients with liver fibrosis, but the mechanisms underlying liver fibrosis remain unclear. Melatonin is a well‐recognized antioxidant and an anti‐inflammatory agent that benefits multiple organs. However, the beneficial effects of melatonin on gut leakiness–associated liver fibrosis have not been systemically studied. Here, we investigated the protective mechanisms of melatonin against thioacetamide (TAA)–induced gut barrier dysfunction and hepatic fibrosis by focusing on posttranslational protein modifications through the gut–liver axis. Our results showed that gut leakiness markers, including decreased gut tight/adherens junction proteins (TJ/AJs) with increased intestinal deformation, apoptosis, and serum endotoxin, were observed early at 1 week after TAA exposure. Liver injury, apoptosis, and fibrosis were prominent at 2 and 4 weeks. Mechanistically, we found that gut TJ/AJs were hyper‐acetylated, followed by ubiquitin‐dependent proteolysis, leading to their degradation and gut leakiness. Gut dysbiosis, hepatic protein hyper‐acetylation, and SIRT1 downregulation were also observed. Consistently, intestinal Sirt1 deficiency greatly enhanced protein hyper‐acetylation, gut leakiness, endotoxemia, and liver fibrosis. Pretreatment with melatonin prevented or improved all these changes in both the gut and liver. Furthermore, melatonin blunted protein acetylation and injury in TAA–exposed T84 human intestinal and AML12 mouse liver cells. Overall, this study demonstrated novel mechanisms by which melatonin prevents gut leakiness and liver fibrosis through the gut–liver axis by attenuating the acetylation of intestinal and hepatic proteins. Thus, melatonin consumption can become a potentially safe supplement for liver fibrosis patients by preventing protein hyper‐acetylation and gut leakiness.